How to prevent the microvascular complications of type 2 diabetes beyond glucose control

Willy Marcos Valencia, Hermes J Florez

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Microvascular complications (retinopathy, nephropathy, and neuropathy) affect hundreds of millions of patients with type 2 diabetes. They usually affect people with longstanding or uncontrolled disease, but they can also be present at diagnosis or in those yet to have a diagnosis made. The presentation and progression of these complications can lead to loss of visual, renal, and neurologic functions, impaired mobility and cognition, poor quality of life, limitations for employment and productivity, and increased costs for the patient and society. If left uncontrolled or untreated, they lead to irreversible damage and even death. This review focuses on the primary and secondary prevention of diabetic microvascular complications in patients with type 2 diabetes, beyond glycemic control. Interventions discussed include standard of care interventions supported by guidelines from major organizations, as well as additional proposed interventions that are supported by research published in the past decade. High level evidence sources such as systematic reviews and large, multicenter randomized clinical trials have been prioritized. Smaller trials were included where high quality evidence was unavailable.

Original languageEnglish (US)
Article numberi6505
JournalBMJ (Online)
Volume356
DOIs
StatePublished - 2017
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Glucose
Diabetes Complications
Primary Prevention
Standard of Care
Secondary Prevention
Cognition
Nervous System
Randomized Controlled Trials
Quality of Life
Organizations
Guidelines
Kidney
Costs and Cost Analysis
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

How to prevent the microvascular complications of type 2 diabetes beyond glucose control. / Valencia, Willy Marcos; Florez, Hermes J.

In: BMJ (Online), Vol. 356, i6505, 2017.

Research output: Contribution to journalReview article

@article{68d1b2f95ad0439c91db7fdf04593db8,
title = "How to prevent the microvascular complications of type 2 diabetes beyond glucose control",
abstract = "Microvascular complications (retinopathy, nephropathy, and neuropathy) affect hundreds of millions of patients with type 2 diabetes. They usually affect people with longstanding or uncontrolled disease, but they can also be present at diagnosis or in those yet to have a diagnosis made. The presentation and progression of these complications can lead to loss of visual, renal, and neurologic functions, impaired mobility and cognition, poor quality of life, limitations for employment and productivity, and increased costs for the patient and society. If left uncontrolled or untreated, they lead to irreversible damage and even death. This review focuses on the primary and secondary prevention of diabetic microvascular complications in patients with type 2 diabetes, beyond glycemic control. Interventions discussed include standard of care interventions supported by guidelines from major organizations, as well as additional proposed interventions that are supported by research published in the past decade. High level evidence sources such as systematic reviews and large, multicenter randomized clinical trials have been prioritized. Smaller trials were included where high quality evidence was unavailable.",
author = "Valencia, {Willy Marcos} and Florez, {Hermes J}",
year = "2017",
doi = "10.1136/bmj.i6505",
language = "English (US)",
volume = "356",
journal = "The BMJ",
issn = "0959-8138",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - How to prevent the microvascular complications of type 2 diabetes beyond glucose control

AU - Valencia, Willy Marcos

AU - Florez, Hermes J

PY - 2017

Y1 - 2017

N2 - Microvascular complications (retinopathy, nephropathy, and neuropathy) affect hundreds of millions of patients with type 2 diabetes. They usually affect people with longstanding or uncontrolled disease, but they can also be present at diagnosis or in those yet to have a diagnosis made. The presentation and progression of these complications can lead to loss of visual, renal, and neurologic functions, impaired mobility and cognition, poor quality of life, limitations for employment and productivity, and increased costs for the patient and society. If left uncontrolled or untreated, they lead to irreversible damage and even death. This review focuses on the primary and secondary prevention of diabetic microvascular complications in patients with type 2 diabetes, beyond glycemic control. Interventions discussed include standard of care interventions supported by guidelines from major organizations, as well as additional proposed interventions that are supported by research published in the past decade. High level evidence sources such as systematic reviews and large, multicenter randomized clinical trials have been prioritized. Smaller trials were included where high quality evidence was unavailable.

AB - Microvascular complications (retinopathy, nephropathy, and neuropathy) affect hundreds of millions of patients with type 2 diabetes. They usually affect people with longstanding or uncontrolled disease, but they can also be present at diagnosis or in those yet to have a diagnosis made. The presentation and progression of these complications can lead to loss of visual, renal, and neurologic functions, impaired mobility and cognition, poor quality of life, limitations for employment and productivity, and increased costs for the patient and society. If left uncontrolled or untreated, they lead to irreversible damage and even death. This review focuses on the primary and secondary prevention of diabetic microvascular complications in patients with type 2 diabetes, beyond glycemic control. Interventions discussed include standard of care interventions supported by guidelines from major organizations, as well as additional proposed interventions that are supported by research published in the past decade. High level evidence sources such as systematic reviews and large, multicenter randomized clinical trials have been prioritized. Smaller trials were included where high quality evidence was unavailable.

UR - http://www.scopus.com/inward/record.url?scp=85010430245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010430245&partnerID=8YFLogxK

U2 - 10.1136/bmj.i6505

DO - 10.1136/bmj.i6505

M3 - Review article

VL - 356

JO - The BMJ

JF - The BMJ

SN - 0959-8138

M1 - i6505

ER -